

	Type	L #	Hits	Search Text	Dbs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	1779	thrombin adj inhibitor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/05/3 1 17:36			0
2	BRS	L2	78	1 same prodrug	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/05/3 1 17:37			0
3	BRS	L3	1	kit same 2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/05/3 1 17:39			0
4	BRS	L4	14	melagatran	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/05/3 1 17:39			0
5	BRS	L5	4	4 same prodrug	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/05/3 1 17:40			0
6	BRS	L6	1	5 same kit	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/05/3 1 17:41			0
7	BRS	L7	1	(2 or 5) same (composition or formulation)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/05/3 1 17:44			0
8	BRS	L8	1	(2 or 5) same carrier	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/05/3 1 17:44			0

FILE 'HOME' ENTERED AT 17:48:05 ON 31 MAY 2002

=> file medline caplus biosis embase scisearch agricola

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 17:48:43 ON 31 MAY 2002

FILE 'CAPLUS' ENTERED AT 17:48:43 ON 31 MAY 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:48:43 ON 31 MAY 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 17:48:43 ON 31 MAY 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:48:43 ON 31 MAY 2002

COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 17:48:43 ON 31 MAY 2002

=> s thrombin inhibitor

L1 9688 THROMBIN INHIBITOR

=> s l1 (p) prodrug

L2 44 L1 (P) PRODRUG

=> s l2 (p) kit

L3 0 L2 (P) KIT

=> s melagatran

L4 328 MELAGATRAN

=> s l4 (p) prodrug

L5 26 L4 (P) PRODRUG

=> s l5 (p) kit

L6 0 L5 (P) KIT

=> s (l2 or l5) (p) (composition or formulation)

L7 1 (L2 OR L5) (P) (COMPOSITION OR FORMULATION)

=> d l7 1 ibib abs

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:772474 CAPLUS

DOCUMENT NUMBER: 133:340244

TITLE: A pharmaceutical ***formulation*** comprising a
low molecular weight ***thrombin***
inhibitor and its ***prodrug***

INVENTOR(S): Gustafsson, David

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064470	A1	20001102	WO 2000-SE756	20000419
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,			

SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

SE 9901442 A 20001022 SE 1999-1442 19990421
BR 2000009847 A 20020108 BR 2000-9847 20000419
EP 1200118 A1 20020502 EP 2000-928047 20000419

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL

NO 2001005107 A 20011019 NO 2001-5107 20011019

PRIORITY APPLN. INFO.:

SE 1999-1442 A 19990421
SE 1999-4419 A 19991203
WO 2000-SE756 W 20000419

OTHER SOURCE(S): MARPAT 133:340244

AB A pharmaceutical ***formulation*** contains a low mol. wt.
thrombin ***inhibitor***, or a pharmaceutically acceptable
deriv. with an adjuvant, diluent or carrier; a pharmaceutical
formulation including a ***prodrug*** of a low mol. wt.
thrombin ***inhibitor***, or a deriv. of that ***prodrug***
, in admixt. with an adjuvant, diluent or carrier. The
formulation is suitable for administration in the treatment of a
condition in which the inhibition of thrombin is required. A controlled,
randomized, parallel group, Swedish multi-center pilot study was carried
out. The study was open with regard to the drugs under evaluation but was
blind for the patients, all personnel at the study sites, and for the
person monitoring the expts. with regard to the doses of
melagatran and the ***prodrug*** of ***melagatran***,
EtOOC-CH₂-(R)Cgl-Aze-Pab-OH (I). A combination of s.c. administered
melagatran and orally administered I is effective in preventing
venous thrombosis after orthopedic surgery.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:48:05 ON 31 MAY 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
17:48:43 ON 31 MAY 2002

L1 9688 S THROMBIN INHIBITOR
L2 44 S L1 (P) PRODRUG
L3 0 S L2 (P) KIT
L4 328 S MELAGATRAN
L5 26 S L4 (P) PRODRUG
L6 0 S L5 (P) KIT
L7 1 S (L2 OR L5) (P) (COMPOSITION OR FORMULATION)

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	21.60	21.81
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.62	-0.62

STN INTERNATIONAL LOGOFF AT 17:51:27 ON 31 MAY 2002